Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX)

CUSIP: 68235C206

Q2 2024 13F Holders as of 30 Jun 2024

Type / Class
Equity / Common Stock, no par value
Shares outstanding
32,330,312
Total 13F shares
5,990,280
Share change
+2,431,030
Total reported value
$17,670,609
Price per share
$2.95
Number of holders
21
Value change
+$7,170,223
Number of buys
9
Number of sells
9

Quarterly Holders Quick Answers

What is CUSIP 68235C206?
CUSIP 68235C206 identifies IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
BROADWOOD CAPITAL INC
13F
Company
7.8%
2,509,066
$7,351,563 31 Mar 2024
13F
PURA VIDA INVESTMENTS, LLC
3/4/5 13F
10%+ Owner · Company
1.6%
from 13F
16,591,052
mixed-class rows
$3,044,309 14 Apr 2023
AWM Investment Company, Inc.
13F
Company
2.6%
754,286
$2,210,058 31 Mar 2024
13F
VANGUARD GROUP INC
13F
Company
0.77%
247,873
$726,267 31 Mar 2024
13F
MORGAN STANLEY
13F
Company
0.38%
123,211
$361,008 31 Mar 2024
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.19%
62,433
$182,987 31 Mar 2024
13F
BlackRock Finance, Inc.
13F
Company
0.19%
60,187
$176,348 31 Mar 2024
13F
Defender Capital, LLC.
13F
Company
0.2%
55,885
$163,743 31 Mar 2024
13F
John Peter Gutfreund
3/4/5
Former Director
mixed-class rows
760,000
mixed-class rows
$153,654 30 Jun 2023
Ronald Asbury Andrews
3/4/5
Former CEO, Director
mixed-class rows
633,212
mixed-class rows
$125,332 01 Dec 2022
Alfred D. Kingsley
3/4/5
Director
mixed-class rows
597,878
mixed-class rows
$109,143 23 Jun 2023
Gisela Paulsen
3/4/5
Former President and COO
class O/S missing
366,500
$78,761 16 Dec 2022
Li Yu
3/4/5
VP Cntrllr/Prncpl Acctng Offcr
mixed-class rows
41,872
mixed-class rows
$76,536 18 May 2022
Ross Douglas T.
3/4/5
Former CSO
class O/S missing
234,114
$50,311 21 Dec 2022
STATE STREET CORP
13F
Company
0.05%
16,289
$47,727 31 Mar 2024
13F
RENAISSANCE TECHNOLOGIES LLC
13F
Company
0.04%
12,218
$36,000 31 Mar 2024
13F
Cavan M. Redmond
3/4/5
Director
class O/S missing
120,863
$25,973 24 Jun 2022
Mitchell S. Levine
3/4/5
Chief Financial Officer
mixed-class rows
174,580
mixed-class rows
$18,713 15 Mar 2022
Jennifer Levin Carter
3/4/5
Director
mixed-class rows
75,500
mixed-class rows
$6,554 15 Aug 2022
Melinda Griffith
3/4/5
Director
mixed-class rows
75,000
mixed-class rows
$6,447 15 Aug 2022
Tower Research Capital LLC (TRC)
13F
Company
0.01%
1,880
$5,508 31 Mar 2024
13F
UBS Group AG
13F
Company
0%
864
$2,532 31 Mar 2024
13F
PNC FINANCIAL SERVICES GROUP, INC.
13F
Company
0%
500
$1,465 31 Mar 2024
13F
NBC SECURITIES, INC.
13F
Company
0%
150
$1,000 31 Mar 2024
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
210
$615 31 Mar 2024
13F
JPMORGAN CHASE & CO
13F
Company
0%
154
$451 31 Mar 2024
13F
OSAIC HOLDINGS, INC.
13F
Company
0%
97
$284 31 Mar 2024
13F
WELLS FARGO & COMPANY/MN
13F
Company
0%
61
$179 31 Mar 2024
13F
Riggs Asset Managment Co. Inc.
13F
Company
0%
50
$147 31 Mar 2024
13F
Piscataqua Savings Bank
13F
Company
0%
25
$73 31 Mar 2024
13F
COMERICA BANK
13F
Company
0%
23
$67 31 Mar 2024
13F
FMR LLC
13F
Company
0%
13
$38 31 Mar 2024
13F
ALBION FINANCIAL GROUP /UT
13F
Company
0%
7
$21 31 Mar 2024
13F
Qube Research & Technologies Ltd
13F
Company
0%
1
$3 31 Mar 2024
13F
Anish M. John
3/4/5
Chief Financial Officer
class O/S missing
121,381
24 Feb 2023
Padmavathi Sundar
3/4/5
Chief Commercial Officer
class O/S missing
87,500
15 Mar 2022

Institutional Holders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) as of Q2 2024

As of 30 Jun 2024, Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) was held by 21 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 5,990,280 shares. The largest 10 holders included BROADWOOD CAPITAL INC, PURA VIDA INVESTMENTS, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, BlackRock Inc., FNY Investment Advisers, LLC, STATE STREET CORP, NORTHERN TRUST CORP, and RENAISSANCE TECHNOLOGIES LLC. This page lists 21 institutional shareholders reporting positions in this security for the Q2 2024 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
22
Q2 2024 holders
21
Holder diff
-1
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 Value $ Q2 2024 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .